1,25 $
5,93 %vorgestern
Nasdaq, 23. Februar, 22:08 Uhr
ISIN
US09609G1004
Symbol
BLUE
Berichte
Sektor
Industrie

bluebird bio, Inc. Aktie News

Neutral
MarketBeat
10 Tage alt
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX ...
Negativ
The Motley Fool
etwa 2 Monate alt
Bluebird Bio's latest gene-editing therapy could have safety problems. The treatment's price also seems high compared to a notable competitor.
Neutral
MarketBeat
etwa 2 Monate alt
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
Neutral
Business Wire
etwa 2 Monate alt
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (the Company; bluebird) today announced updates to be presented at the 42nd Annual J.P. Morgan Healthcare conference including commercial launch progress, 2024 program milestones and financial outlook. Andrew Obenshain, chief executive officer, is scheduled to present Tuesday, January 9 at 10:30 a.m. PT/1:30 p.m. ET. “In 2023...
Neutral
Business Wire
etwa 2 Monate alt
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30am PT/1:30pm ET. To access the live webcast of bluebird bio's presentation, please visit the “Events & Presentations” page with...
Negativ
The Motley Fool
2 Monate alt
Investors may be tempted to go bottom-fishing after BlueBird Bio's share price drawdown. However, competition from two rivals and a large stock offering should make investors think twice.
Neutral
The Motley Fool
2 Monate alt
Bluebird Bio has proven its innovative capabilities. However, the company likely won't turn a profit soon.
Negativ
The Motley Fool
2 Monate alt
By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen